	OMB APPROVAL
	OMB Number: Expires:
	Estimated average burden hours per form
SECURITIES AND	TED STAES EXCHANGE COMMISSION on, D.C. 20549
SCHE	DULE 13D
	es Exchange Act of 1934 Iment No. 1)*
SIGA PHARM	MACEUTICALS, INC.
(Name	e of Issuer)
Com	nmon Stock
(Title of Cl	ass of Securities)
	6 917 10 6
	SIP Number)
Ehrenreich Ei 11 East 44th New York,	Eilenberg, Esq. lenberg & Krause LLP Street, 17th Floor New York 10017 2) 986-9700
	elephone Number of Person Notices and Communications)
Decem	ıber 29, 1999
	which Requires Filing s Statement)
If the filing person has previously the acquisition which is the subjec schedule because of Rule 13d-1(b)(3)	filed a statement of Schedule 13G to report of the Schedule 13D, and is filing this or (4), check the following box [].
(A fee is not required only if th statement on file reporting benefic the class of securities described	e is being paid with this statement [X]. ne reporting person: (1) has a previous sial ownership of more than five percent of in Item 1; and (2) has filed no amendment ficial ownership of five percent or less of
	ncluding all exhibits, should be filed with for other parties to whom copies are to be

*The remainder of this cover page shall be filed out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 82	6 917 10 6 13D	
	REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON	
Richard Stone		
2 CHECK T	HE APPROPRIATE BOX IF A MEMBER OF A GROUP*	
	(a) [] (b) [X]	
3 SEC USE	ONLY	
4 SOURCE	OF FUNDS*	
	PF	
5 CHECK B	OX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO	
	(d) OR 2(e) []	
6 CITIZEN	SHIP OR PLACE OF ORGANIZATION	
USA		
NUMBER OF SHARES	7 SOLE VOTING POWER 548,465	
BENEFICIALLY OWNED BY		
EACH REPORTING	0	
PERSON WITH	9 SOLE DISPOSITIVE POWER 548,465	
	10 SHARED DISPOSITIVE POWER	
	Θ	
11 AGGREGA	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
548,46		
	-	
12 CHECK E	OX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
	[]	
13 PERCENT	OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
8.3%		
0.5%		
14 TYPE OF	REPORTING PERSON*	
IN		
	*SEE INSTRUCTIONS BEFORE FILLING OUT!	

Item 1. Security and Issuer.

The title of the class of equity securities to which this statement relates is the common stock, \$.0001 par value per share (the "Common Stock"), of SIGA Pharmaceuticals, Inc., a Delaware corporation (the "Company"). The principal executive offices of the Company are located at 420 Lexington Avenue, Suite 620, New York, NY 10170. This statement is filed pursuant to Rule 13d-2(a) with respect to securities owned by Richard Stone as of December 29, 1999 and amends the Schedule 13 D filed on June 3, 1998 (the "Schedule 13D").

Item 2. Identity and Background.

- (a) The name of the person filing this Schedule 13D is Richard Stone.
- (b) The business address of Mr. Stone is c/o Sunrise Securities Corp., 135 East 57th Street, 11th Floor, New York, New York 10022.
- (c) Mr. Stone is a Managing Director of Sunrise Securities Corp., a registered broker-dealer.
- (d) Mr. Stone has not been convicted during the past five years in a criminal proceeding (excluding traffic violations or similar misdemeanors).
- (e) Mr. Stone has not been, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and has not and is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) Mr. Stone is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration.

In addition to the shares previously reported on his Schedule 13D filed June 3, 1998, Mr. Stone purchased an aggregate of 77,800 shares of Common Stock in open-market purchases made during the period commencing July 14, 1998 and ended December 29, 1999. The purchase price of the shares of Common Stock ranged between \$3.25 per share and \$1.0625 per share and all purchases by Mr. Stone were paid out of his personal funds.

Item 4. Purpose of Transaction.

Such acquisitions of securities were made for investment purposes. Although he has no current intention to do so, depending on market conditions and other factors, Mr. Stone may acquire additional shares, or sell all or a portion of his shares of Common Stock. Mr. Stone

has no current plans or proposals which relate to or would result in any of the actions set forth in subparagraphs (a) through (j) of Item 4.

Item 5. Interest in Securities of the Issuer.

See Items 7 through 11 on the cover page. During the period commencing July 14, 1998 and ended December 29, 1999, Mr. Stone purchased an aggregate of 77,800 shares of Common Stock in open-market purchases with personal funds.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

None.

Item 7. Materials to be Filed as Exhibits.

None.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 14, 2000

/s/ Richard Stone Richard Stone

(120496DTI)